Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adderall XR Sales Rebounding, Shire Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Sales of Shire's attention deficit/hyperactivity disorder agent Adderall XR (extended-release amphetamine) are rebounding after negative publicity that followed Health Canada's suspension of the product

You may also be interested in...



Shire/TKT Merger Deal Focuses On Dynepo Rights In Europe

Shire will promote TKT's Dynepo in Europe with part of its 200-person Fosrenol sales force. European rights to the erythropoietin product were one of the critical components to the $1.6 bil. acquisition. The deal also brings Shire two products in development.

ADHD Market Hurt By Safety Concerns, Lilly Says

Strattera marketer says that label change and withdrawal of Shire's Adderall XR in Canada has slowed the growth of the attention deficit/hyperactivity disorder market. Lilly will focus on consumers with new DTC ad designed to encourage adult patients to seek treatment.

Shire Adderall XR Sales Suspended In Canada; FDA Stands By "Black Box"

Company plans a "Dear Doctor" letter informing U.S. physicians of Health Canada's decision. FDA says it "has not decided to take any further regulatory action at this time"; sudden death warnings were added to Adderall XR's labeling in August.

Related Content

Topics

UsernamePublicRestriction

Register

PS062040

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel